U.S. regulators approved AstraZeneca’s key immunotherapy drug Imfinzi (durvalumab) as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars.

A second baby with aggressive leukemia has been treated in London with “designer immune cells” developed by Cellectis and, six months after treatment, she remains in remission.

January 27, 2016By Mark Terry, BioSpace.com Breaking News Staff   Menlo Park, Calif.-based Adicet Bio, Inc. announced today that it had closed on a $51 million Series A financing round. The financing was led by OrbiMed and joined by Novartis Venture Fund and Pontifax. In addition, Adicet announced it had acquired Israeli company Applied Immune […]

Atara Biotherapeutics Inc said it would stop developing its kidney drug after the treatment failed to meet the main goal of a mid-stage study. The drug developer said on Monday that the drug, PINTA 745, did not improve physical function, levels of inflammation and blood sugar in patients in the study. Atara’s shares fell nearly […]

(Reuters) – A baby whom doctors thought almost certain to die has been cleared of a previously incurable leukemia in the first human use of an “off-the-shelf” cell therapy from Cellectis that creates designer immune cells. One-year-old Layla had run out of all other treatment options when doctors at Britain’s Great Ormond Street Hospital (GOSH) […]